Q1 2023 Earnings Presentation
GROUP OVERVIEW
Constant Currency Q1 2023 Revenue Performance Year-over-Year(¹)
AVANCE III HD
B
www
W
2023 Bruker
CARE of you
Innovation with integ
20
BROKER
TEL
Bruker BioSpin Group
BioSpin up high-teens %, on solid customer demand and aftermarket growth; bookings
stronger than revenues, including strong China bookings
BRUKER
Solid performance in NMR, even without any GHz-class systems in Q1-23 revenue. Now
expect 3-4 GHz-class NMRs in H2-23 revenue, with none in H1-23 revenue.
Preclinical Imaging with strong revenue growth
Bruker CALID Group
CALID up low-20s% range, driven by robust life science mass spectrometry; bookings stronger
than revenues
▪ Life science mass spectrometry driven by proteomics demand for timsTOF
Bruker Optics with strong growth, especially in China
Microbiology & Infection Diagnostics (MID) down slightly on strong Q1-22; aftermarket
strength partially offset by slower instrument revenue
(1) All in constant currency, and in comparison to Q1 2022
Q1 2023 Earnings Presentation 1
May 4, 2023
I
LO
5View entire presentation